Alkandari D, Herbert JA, Alkhalaf MA, Yates C, Panagiotou S. SARS-CoV-2 vaccines: fast track versus efficacy. Lancet Microbe. 2021;2(3):e89–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
WHO. Draft landscape and tracker of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed January 23, 2021.
CDC A. https://africacdc.org/covid-19/.
Batchi-Bouyou AL, LobalobaIngoba L, Ndounga M, Vouvoungui JC, MfoutouMapanguy CC, Boumpoutou KR, et al. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo. Int J Infect Dis. 2021;106:3–7.
Article
CAS
PubMed
Google Scholar
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–9.
Article
CAS
PubMed
Google Scholar
Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–6.
Article
CAS
PubMed
Google Scholar
Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020;58(11):e02107-20.
Ntoumi F, MfoutouMapanguy CC, Tomazatos A, Pallerla SR, Linh LTK, Casadei N, et al. Genomic surveillance of SARS-CoV-2 in the Republic of Congo. Int J Infect Dis. 2021;105:735–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lobaloba Ingoba L, Djontu JC, Mfoutou Mapanguy CC, Mouzinga F, Diafouka Kietela S, Vouvoungui C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo. IJID Regions. 2022.
Mukwege D, Byabene AK, Akonkwa EM, Dahma H, Dauby N, CikwanineBuhendwa J-P, et al. High SARS-CoV-2 seroprevalence in healthcare workers in Bukavu, Eastern Democratic Republic of Congo. Am J Trop Med Hyg. 2021;104(4):1526–30.
Article
PubMed
PubMed Central
Google Scholar
Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, et al. High seroprevalence of SARS-CoV-2 eight months after introduction in Nairobi, Kenya. SSRN; 2021.
Iwasaki A. What reinfections mean for COVID-19. Lancet Infect Dis. 2021;21(1):3–5.
Article
CAS
PubMed
Google Scholar
Freed NE, Vlkova M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Methods Protoc. 2020;5(1):bpaa014.
Article
PubMed
PubMed Central
Google Scholar
Github. https://github.com/artic-network/fieldbioinformatics.
Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data—from vision to reality. Euro Surveill. 2017;22(13):30494. https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494.
Article
PubMed
PubMed Central
Google Scholar
O’Toole A, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021;7(2):veab064.
Article
PubMed
PubMed Central
Google Scholar
Food, Administration D. USA. cPass™ SARS-CoV-2 neutralization antibody detection kit.
Mutombo PN, Fallah MP, Munodawafa D, Kabel A, Houeto D, Goronga T, et al. COVID-19 vaccine hesitancy in Africa: a call to action. Lancet Glob Health. 2022;10(3):e320-e1.
Chia WN, Zhu F, Ong SWX, Young BE, Fong S-W, Le Bert N, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2(6):e240–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol. 2021;18(4):936–44.
Article
PubMed
Google Scholar
Tan CW, Chia WN, Qin X, Liu P, Chen MIC, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol. 2020;38(9):1073–8.
Article
CAS
PubMed
Google Scholar
LobalobaIngoba L, Djontu JC, MfoutouMapanguy CC, Mouzinga F, DiafoukaKietela S, Vouvoungui C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo. IJID Regions. 2022;2:130–6.
Article
Google Scholar
Morales-Núñez JJ, Muñoz-Valle JF, Meza-López C, Wang L-F, Machado Sulbarán AC, Torres-Hernández PC, et al. Neutralizing antibodies titers and side effects in response to BNT162b2 vaccine in healthcare workers with and without prior SARS-CoV-2 infection. Vaccines (Basel). 2021;9(7):742.
Article
Google Scholar
Kim N, Shin S, Minn D, Park S, An D, Park JH, et al. SARS-CoV-2 infectivity and antibody titer reduction for 6 months after second dose of BNT162b2 mRNA vaccine in healthcare workers: a prospective cohort study. J Infect Dis. 2022. https://doi.org/10.1093/infdis/jiac035.
Hueda-Zavaleta M, Gómezdela Torre JC, Cáceres-Del Aguila JA, Muro-Rojo C, De La Cruz-Escurra N, Arenas Siles D, et al. Evaluation of the humoral immune response of a heterologous vaccination between BBIBP-CorV and BNT162b2 with a temporal separation of 7 months, in Peruvian healthcare workers with and without a history of SARS-CoV-2 infection. Vaccines (Basel). 2022;10(4):502.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.
García-Abellán J, Padilla S, Fernández-González M, García JA, Agulló V, Andreo M, et al. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol. 2021;41(7):1490–501.
Article
PubMed
PubMed Central
Google Scholar
Shioda K, Lau MS, Kraay AN, Nelson KN, Siegler AJ, Sullivan PS, et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. Epidemiology. 2021;32(4):518.
Article
PubMed
PubMed Central
Google Scholar
Gerdol M. Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. bioRxiv. 2021:2021.04.17.440288.
Brito AF, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MU, et al. Global disparities in SARS-CoV-2 genomic surveillance. medRxiv. 2021. https://doi.org/10.1101/2021.08.21.21262393.
Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41(5):355–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang AT, Garcia-Carreras B, Hitchings MD, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):1–16.
Article
Google Scholar
Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. Morb Mortal Wkly Rep. 2021;70(32):1081.
Article
CAS
Google Scholar
Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483-95.
Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan H-X, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12(1):1–11.
Article
Google Scholar
Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372–4.
Article
CAS
PubMed
Google Scholar
Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397(10280):1178–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. Infection-and vaccine-induced antibody binding and neutralization of the B. 1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021;29(4):516-21. e3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RE, Stumpf S, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477-88.e4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Plante JA, Mitchell BM, Plante KS, Debbink K, Weaver SC, Menachery VD. The variant Gambit: COVID-19’s next move. Cell Host Microbe. 2021;29(4):508–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, et al. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021;83(4):e1–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States. Clin Infect Dis. 2021;384:ciab687. https://doi.org/10.1093/cid/ciab687.
Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27(12):2127–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Paris C, Perrin S, Hamonic S, Bourget B, Roué C, Brassard O, et al. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data. Clin Microbiol Infect. 2021;27(11):1699.e5-e8.
Article
CAS
Google Scholar
Trovato M, Sartorius R, D’Apice L, Manco R, De Berardinis P. Viral emerging diseases: challenges in developing vaccination strategies. Front Immunol. 2020;11:2130. https://doi.org/10.3389/fimmu.2020.02130.
Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369(6511):1586–92.
Article
CAS
PubMed
Google Scholar
Liu C, Mendonça L, Yang Y, Gao Y, Shen C, Liu J, et al. The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by cryo-EM and cryo-ET. Structure (London, England: 1993). 2020;28(11):1218-24.e4.
Article
CAS
PubMed Central
Google Scholar
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81.
Article
CAS
PubMed
Google Scholar
Coughlan L. Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.
Article
CAS
PubMed
PubMed Central
Google Scholar